MARKSANS.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 11:59):

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide...

Stats
Dagens volum	870 778
Gjennomsnittsvolum	1.88M
Markedsverdi	76.65B
EPS	INR0 ( 2024-02-14 )
Neste inntjeningsdato	( INR0 ) 2024-05-27
Last Dividend	INR0.500 ( 2023-06-07 )
Next Dividend	INR0 ( N/A )
P/E	23.96
ATR14	INR0.255 (0.15%)

Volum Korrelasjon

Lang: -0.02 (neutral)

Kort: -0.41 (neutral)

Signal:(55.54) Neutral

Marksans Pharma Limited Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Marksans Pharma Limited Korrelasjon - Valuta/Råvare

0.14
( neutral )

0.25
( neutral )

0.50
( weak )

0.16
( neutral )

-0.02
( neutral )

0.46
( neutral )

Marksans Pharma Limited Økonomi

Annual	2022
Omsetning:	INR18.52B
Bruttogevinst:	INR9.31B (50.25 %)
EPS:	INR6.41

FY	2022
Omsetning:	INR18.52B
Bruttogevinst:	INR9.31B (50.25 %)
EPS:	INR6.41

FY	2022
Omsetning:	INR14.80B
Bruttogevinst:	INR7.32B (49.46 %)
EPS:	INR4.56

FY	2021
Omsetning:	INR13.68B
Bruttogevinst:	INR7.50B (54.79 %)
EPS:	INR5.83

Financial Reports:

No articles found.

Marksans Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0.250 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0.500 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Marksans Pharma Limited Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.54 - low (50.90%) | Divividend Growth Potential Score: 5.08 - Stable (1.58%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.100	2014-09-18
Last Dividend	INR0.500	2023-06-07
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	10	--
Total Paid Out	INR1.590	--
Avg. Dividend % Per Year	0.40%	--
Score	2.2	--
Div. Sustainability Score	4.54
Div.Growth Potential Score	5.08
Div. Directional Score	4.81	--

Next Divdend (Est)
(2025-03-25)

INR0.618 Estimate 3.11 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.20

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.0500	0.16%
2019	INR0.0500	0.18%
2020	INR0.100	0.58%
2021	INR0.250	0.41%
2022	INR0.250	0.41%
2023	INR0.500	0.85%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SMLT.NS	Dividend Knight	2023-08-09	Semi-Annually	3	0.64%
MIDHANI.NS	Dividend Junior	2023-09-22	Semi-Annually	7	1.04%
HAVELLS.NS	Dividend Junior	2023-06-02	Annually	23	0.43%
BECTORFOOD.NS	Dividend Junior	2023-09-22	Semi-Annually	4	0.39%
PUNJABCHEM.NS	Dividend Junior	2023-07-27	Sporadic	18	0.16%
KENNAMET.NS	Dividend Knight	2023-05-25	Annually	4	0.76%
ELECTCAST.NS	Dividend Junior	2023-09-04	Annually	23	1.51%
AHLUCONT.NS	Dividend Junior	2023-09-22	Sporadic	15	0.04%
SUNPHARMA.NS	Dividend Junior	2023-07-28	Semi-Annually	29	0.77%
NAVA.NS	Dividend Knight	2023-07-24	Annually	23	2.35%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.151	1.500	6.98	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.174	1.500	9.17	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	48.41	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
freeCashFlowPerShareTTM	2.96	2.00	8.52	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.519	1.000	4.69	4.69	[0.2 - 0.8]
operatingProfitMarginTTM	0.203	1.000	7.95	7.95	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.48	1.000	7.63	0	[1 - 100]
returnOnEquityTTM	0.174	2.50	9.47	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
dividendYielPercentageTTM	0.292	1.500	2.71	0	[0 - 0.4]
operatingCashFlowPerShareTTM	2.96	2.00	9.01	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.874	1.500	7.50	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0639	1.000	-0.904	0	[0.1 - 0.5]
Total Score				5.08

Marksans Pharma Limited

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.